P 128 - GangaGen

Drug Profile

P 128 - GangaGen

Alternative Names: P-128 - Gangagen; StaphTAME

Latest Information Update: 02 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GangaGen
  • Class Antibacterials; Recombinant proteins
  • Mechanism of Action Bacterial DNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Staphylococcal infections

Most Recent Events

  • 22 Apr 2017 Preclinical antimicrobial data (in-vitro) presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID-2017)
  • 15 Jul 2016 Early research in Staphylococcal infections in USA (unspecified route)
  • 15 Jul 2016 Preclinical trials in Staphylococcal infections in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top